| Literature DB >> 31141497 |
Thibault Le Roux-Mallouf1, Felix Pelen1, Angela Vallejo1, Idir Halimaoui1, Stéphane Doutreleau1,2, Samuel Verges1,2.
Abstract
Increased nitric oxide (NO) bioavailability may improve exercise performance and vascular function. It remains unclear whether older adults who experience a decreased NO bioavailability may benefit from chronic NO precursor supplementation. This randomised, double-blind, trial aims to assess the effect of chronic NO precursor intake on vascular function and exercise performance in older adults (60-70 years old). Twenty-four healthy older adults (12 females) performed vascular function assessment and both local (knee extensions) and whole-body (incremental cycling) exercise tests to exhaustion before and after one month of daily intake of a placebo (PLA) or a nitrate-rich salad and citrulline (N+C, 520mg nitrate and 6g citrulline) drink. Arterial blood pressure (BP) and stiffness, post-ischemic, hypercapnic and hypoxic vascular responses were evaluated. Prefrontal cortex and quadriceps oxygenation was monitored by near-infrared spectroscopy. N+C supplementation reduced mean BP (-3.3mmHg; p=0.047) without altering other parameters of vascular function and oxygenation kinetics. N+C supplementation reduced heart rate and oxygen consumption during submaximal cycling and increased maximal power output by 5.2% (p<0.05), but had no effect on knee extension exercise performance. These results suggest that chronic NO precursor supplementation in healthy older individuals can reduce resting BP and increase cycling performance by improving cardiorespiratory responses.Entities:
Keywords: ageing; citrulline; exercise; nitrate; nitric oxide
Mesh:
Substances:
Year: 2019 PMID: 31141497 PMCID: PMC6555465 DOI: 10.18632/aging.101984
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Vascular function before and after one month of NO precursor supplementation.
Data are presented as mean ± SD, n = 24. SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, carotid-femoral pulse wave velocity; Reperfusion, difference between the value reached at the end of the ischemic phase and the maximal value reached during the reperfusion phase in the ischemia-reperfusion test; HbO2, oxyhaemoglobin; HbTot, total haemoglobin. PRE, measure before the supplementation period; POST, measure after the supplementation period. N+C, nitrate + citrulline, PLA, placebo; ∆PRE/POST, difference between PRE and POST measures; p∆, p value for ∆PRE/POST group comparison; d∆, Cohen’s d effect size of N+C supplementation on ∆PRE/POST.
Figure 1Individual and group mean changes in mean arterial blood pressure before and after one month of placebo or nitrate and citrulline intake in older adults. N+C, nitrate + citrulline; PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period; * significant difference between PRE and POST; n=24.
Cardiorespiratory, cerebral and muscle responses to hypercapnia before and after one month of NO precursor supplementation.
Data are presented as mean ± SD, n = 24 (n = 23 for TSI). Hypercapnia corresponded to a CO2 end tidal partial pressure of +10 mmHg above normoxic level; ∆HR, Heart rate difference between normoxia and hypercapnia; ∆VE, minute ventilation difference between normoxia and hypercapnia; ∆TSI, tissue saturation index difference between normoxia and hypercapnia; N+C, nitrate + citrulline; PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period. ∆PRE/POST, difference between PRE and POST measures; p∆, p value for ∆PRE/POST group comparison; d∆, Cohen’s d effect size of N+C supplementation on ∆PRE/POST.
Cardiorespiratory, cerebral and muscle responses to hypoxia at rest and during cycling exercise before and after one month of NO precursor supplementation.
Data are presented as mean ± SD, n = 24 (n = 23 for TSI). Hypoxia corresponded to an inspiratory oxygen fraction of 11%. ∆HR, heart rate difference between normoxia and hypoxia; ∆VE, minute ventilation difference between normoxia and hypoxia; ∆SpO2, pulse oxygen saturation difference between normoxia and hypoxia; ∆TSI, tissue saturation index difference between normoxia and hypoxia; PRE, measure before the supplementation period; POST, measure after the supplementation period; N+C, nitrate + citrulline; PLA, placebo; ∆PRE/POST, difference between PRE and POST measures; p∆, p value for ∆PRE/POST group comparison; d∆, Cohen’s d effect size of N+C supplementation on ∆PRE/POST.
Tissue saturation index during the cycling test and knee extension test before and after one month of NO precursor supplementation.
| 1.9 | ± | 4.8 | -4.2 | ± | 3.5 | -1.6 | ± | 1.5 | -5.3 | ± | 4.9 | ||||
| -0.1 | ± | 7.5 | 0.1 | ± | 8.4 | -2.3 | ± | 2.5 | -5.3 | ± | 3.7 | ||||
| -0.9 | ± | 0.5 | -1.0 | ± | 2.0 | 0.9 | ± | 7.8 | -1.1 | ± | 3.5 | ||||
| -1.5 | ± | 0.7 | -2.7 | ± | -3.5 | -2.2 | ± | 1.5 | 3.4 | ± | 1.5 | ||||
| 1.5 | ± | 4.2 | -1.9 | ± | 3.7 | 0.9 | ± | 4.2 | -2.1 | ± | 4.2 | ||||
| -0.6 | ± | 5.0 | -3.0 | ± | 4.8 | -0.6 | ± | 3.7 | -1.8 | ± | 5.7 | ||||
| -9.5 | ± | 8.3 | -8.3 | ± | 11.6 | -9.4 | ± | 6.4 | -8.0 | ± | 9.0 | ||||
| -11.2 | ± | 4.9 | -12.5 | ± | 7.4 | -12.4 | ± | 7.2 | -12.0 | ± | 9.4 | ||||
Data are presented as mean ± SD changes of tissue saturation index in % from the initial workload (70 W for males and 50 W for females), n = 23. N+C, nitrate + citrulline; PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period; 50%, 50% of the duration of the PRE test (i.e. isowatt for cycling exercise and isoKg for knee extension exercise). No interaction effect N+C/PLA group × PRE/POST session, all p > 0.05; all Partial eta square < 0.07.
Performances during the cycling test and the knee extension test before and after one month of NO precursor supplementation.
| 180.9 | ± | 44.3 | 190.3 | ± | 47.5 | 9.4 | ± | 11.1 | 0.021 | 0.411 | ||
| 206.0 | ± | 54.5 | 207.4 | ± | 53.9 | 1.3 | ± | 7.2 | ||||
| 39.6 | ± | 7.3 | 40.6 | ± | 6.5 | 1.2 | ± | 3.8 | 0.920 | 0.040 | ||
| 45.4 | ± | 7.7 | 46.6 | ± | 7.9 | 1.4 | ± | 2.8 | ||||
| 63.1 | ± | 14.0 | 65.6 | ± | 18.0 | 2.5 | ± | 7.6 | 0.350 | 0.340 | ||
| 67.3 | ± | 9.6 | 65.5 | ± | 12.3 | 0.2 | ± | 5.5 | ||||
| 149.0 | ± | 44.0 | 153.0 | ± | 46.0 | 4.1 | ± | 35.1 | 0.650 | 0.020 | ||
| 161.0 | ± | 33.0 | 165.0 | ± | 48.0 | 5.0 | ± | 33.2 | ||||
Data are presented as mean ± SD, n = 24. MVC, maximal voluntary contraction; VO2max, maximal oxygen consumption; N+C, nitrate + citrulline, PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period; ∆PRE/POST, difference between PRE and POST measures; p∆, p value for ∆PRE/POST group comparison; d∆, Cohen’s d effect size of N+C supplementation on ∆PRE/POST.
Figure 2Heart rate and oxygen consumption during the cycling incremental test before and after one month of placebo or nitrate and citrulline intake in older adults. HR, heart rate; VO2, oxygen consumption; N+C, nitrate + citrulline; PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period; 25%; 50%; 75%; 100%, 25%, 50%, 75% and 100%, of the duration of the PRE test (i.e. isowatt).
Figure 3Individual and group mean changes in maximal cycling power output before and after one month of placebo or nitrate and citrulline intake in older adults. N+C, nitrate + citrulline; PLA, placebo; PRE, measure before the supplementation period; POST, measure after the supplementation period; * significant difference between PRE and POST; n=24.
Figure 4Overview of the study design.